Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …

Pancreatic stellate cell (PSC) is a type of pluripotent cell located between pancreatic lobules
and the surrounding area of acinars. When activated, PSC can be transformed into …

Experimental evidence indicates that mesenchymal stromal cells (MSCs) may regulate
tumor microenvironment (TME). It is conceivable that the interaction with MSC can influence …

Background Gemcitabine remains a cornerstone in chemotherapy of pancreatic ductal
adenocarcinoma (PDAC) despite suboptimal clinical effects that are partly due to the …

The stroma is a main driver of metastasis and aggressiveness in pancreatic cancer (PC),
one of the deadliest malignancies worldwide. Pancreatic stellate cells (PSCs) form …

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer
and carries the worst prognosis of all common cancers. Five-year survival rates have not …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer with
poor prognosis because it is highly resistant to traditional chemotherapy and radiotherapy …

Pancreatic cancer (PC) is very deadly and difficult to treat. The presence of hypoxia has
been shown to increase the probability of cancer developing and spreading. Pancreatic …

Activated pancreatic stellate cells (PSCs) play a central role in the tumor stroma of
pancreatic ductal adenocarcinoma (PDAC). Given the limited availability of patient-derived …

Simple Summary The great majority, more than 90%, of patients with pancreatic ductal
adenocarcinoma (PDAC) die within less than five years after detection of the disease …